Grace Therapeutics, Inc.

Analysis for Ticker: GRCE

Grace Therapeutics Inc is a bio-pharmaceutical company that uses nanoparticle technology to improve existing medications for the treatment of rare and orphan diseases. The internal math reveals a corporate machine engineered for the extraction of capital rather than the advancement of medicine. Since its inception, the company has burned through an accumulated deficit exceeding 224$ million while generating exactly 0$ in product revenue. Despite these massive losses, the entire operation is run by a staff of only six employees. This is like a lemonade stand that spends 224$ million on fancy cups, high-priced lawyers, and executive bonuses but has never actually sold a single cup of lemonade. The core business is the systematic transfer of investor wealth into the pockets of a small group of insiders through highly complex legal contracts. The financial narrative began with a massive net loss of 42,4$ million in the fiscal year ending in 03/2023. To keep the host alive, the company executed a private placement in 09/2023 to raise 7,3$ million in net proceeds by selling 1.951.371 shares to institutional investors at 1,848$ per share. To entice these buyers, the company attached pre-funded warrants for 2.106.853 shares and common warrants for another 2.536.391 shares. These pre-funded warrants are the primary mechanism of the financial crime; they allow insiders to buy shares for exactly 0,0001$ each, which is essentially free money. The participants in this feast included funds like AIGH Capital Management, Nantahala Capital Management, and ADAR1 Capital Management, as well as Shore Pharma LLC, a trust held for the immediate family of the board chairman, Vimal Kavuru. These entities used legal ownership caps of 4,99% or 9,99% to hide the fact that they held millions of additional shares in the form of unexercised warrants.